ASCENIV- human immunoglobulin g liquid
ADMA Biologics, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use ASCENIV ™ safely and effectively.

See full prescribing information for ASCENIV.

ASCENIV (immune globulin intravenous, human – slra)

10% Liquid

Initial U.S. Approval: 2019

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

See full prescribing information for complete boxed warning.

- **Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. [5.2]**
- **Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. [5.3]**
- **For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [5.2,5.3]**

RECENT MAJOR CHANGES

Boxed Warning (5.3) 04/2026
Indications and Usage (1) 04/2026
Dosage and Administration, Dose (2.1) 09/2026

INDICATIONS AND USAGE

ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. (1)

DOSAGE AND ADMINISTRATION

For intravenous use only. (2)
(2)

Dose	Initial Infusion Rate	Maintenance Infusion Rate (if tolerated)
300-800 mg/kg every 3-4 weeks	0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutes	Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)

(2)

DOSAGE FORMS AND STRENGTHS

ASCENIV is a liquid solution containing 10% IgG (100 mg/mL) for intravenous infusion; (5g in 50 mL solution). [3]

CONTRAINDICATIONS

- History of anaphylactic or severe systemic reactions to human immunoglobulin. [4]
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. [4, 5.1]

WARNINGS AND PRECAUTIONS

- IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
- Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
- In patients at risk of developing acute renal failure. monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
- Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]
- Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
- Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
- Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil

antibodies. [5.7]
- Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]

ADVERSE REACTIONS

The most common adverse reactions to ASCENIV (≥5% of study patients) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea. [6]

To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (1-800-458-4244) or FDA at 1-800-FDA-1088 or *www.fda.gov/medwatch.*

DRUG INTERACTIONS

- Passive transfer of antibodies may transiently interfere with the immune response to live virus vaccines, such as measles, mumps, rubella, and varicella. [7]
- Passive transfer of antibodies may confound the results of serological testing. [5.10]

USE IN SPECIFIC POPULATIONS

Geriatric Use: In patients over age 65 or in any patient at risk of developing renal insufficiency, do not exceed the recommended dose, and infuse ASCENIV at the minimum infusion rate practicable. [8.5]

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 9/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Dose
2.2 Preparation and Handling
2.3 Administration
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypersensitivity
5.2 Thrombosis
5.3 Renal Injury
5.4 Hyperproteinemia, Hyperviscosity, and Hyponatremia
5.5 Aseptic Meningitis Syndrome
5.6 Hemolysis
5.7 Transfusion-Related Acute Lung Injury
5.8 Transmissible Infectious Agents
5.9 Monitoring Laboratory Tests
5.10 Interference with Laboratory Tests
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE

- **Thrombosis may occur with immune globulin (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors (see *Warnings and Precautions [5.2]).***
- **Renal dysfunction, acute renal failure, osmotic nephrosis may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs *[see Warnings and Precautions (5.3)].***
- **For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity (*see Dosage and Administration [2.1, 2.3],Warnings and Precautions [5.3]).***

1 INDICATIONS AND USAGE

ASCENIV is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

2 DOSAGE AND ADMINISTRATION

2.1 Dose

For intravenous use only.

Table 1: Recommended Dosage for ASCENIV

Dose	**Initial Infusion Rate**	**Maintenance Infusion Rate (if tolerated)**
300-800 mg/kg every 3-4 weeks	0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutes	Increase gradually every 15 minutes (if tolerated) up to 8 mg/kg/min (0.08 mL/kg/min)

Measles Exposure

If a patient has been exposed to measles, it may be prudent to administer an extra dose of IGIV as soon as possible and within 6 days of exposure. A dose of 400 mg/kg should provide a serum level> 240 mIU/mL of measles antibodies for at least two weeks.

If a patient is at risk of future measles exposure and receives a dose of less than 530 mg/kg every 3-4 weeks, the dose should be increased to at least 530 mg/kg. This should provide a serum level of 240 mIU/mL of measles antibodies for at least 22 days after infusion.

2.2 Preparation and Handling

- ASCENIV is a clear to opalescent, colorless to pale yellow solution. Inspect visually for particulate matter and discoloration prior to administration. Do not use if the liquid is cloudy or turbid, or if it contains visible particulate matter.
- Allow refrigerated product to come to room temperature before use and maintain ASCENIV at room temperature during administration.
- DO NOT MICROWAVE.
- DO NOT SHAKE.
- DO NOT MIX with other IGIV products or other intravenous medications.
- DO NOT DILUTE.
- ASCENIV contains no preservatives. Each vial is for single use only. Do not reuse or save for future use.
- If large doses are required, several vials may be pooled using aseptic technique into sterile infusion bags and infused.

2.3 Administration

- Begin with an initial infusion rate of 0.5 mg/kg/min. If there are no adverse reactions, the infusion rate for subsequent infusions can be slowly increased to the maximum rate.
- Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a slower rate which is comfortable for the patient.
- Ensure that patients with pre-existing renal insufficiency are not volume-depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer ASCENIV at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates (*see Boxed Warning, Warnings and Precautions [5.2, 5.3]*).

3 DOSAGE FORMS AND STRENGTHS

ASCENIV is a liquid solution containing 10% IgG (100 mg/mL) for intravenous infusion. ASCENIV is supplied in 50 mL single-dose vial.

4 CONTRAINDICATIONS

ASCENIV is contraindicated in:

- patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin.
- IgA-deficiency patients with antibodies to IgA and a history of hypersensitivity. [see Warnings and Precautions (5.1)]

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity

Severe hypersensitivity reactions may occur with IGIV products, including ASCENIV. In case of hypersensitivity, discontinue ASCENIV infusion immediately and institute appropriate treatment. Medications such as epinephrine should be available for treatment of acute hypersensitivity reactions.

ASCENIV contains IgA ≤ 200 micrograms per milliliter (see *Description [11]*). Patients with known antibodies to IgA may have a greater risk of developing severe hypersensitivity and anaphylactic reactions. ASCENIV is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity reaction (see *Contraindications [4]*).

5.2 Thrombosis

Thrombosis may occur following treatment with immune globulin products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.

Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer ASCENIV at the minimum dose and infusion rate practicable.

Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity (see Boxed Warning, Dosage and Administration [2]).

5.3 Renal Injury

Renal injury including acute renal dysfunction, acute renal failure, acute tubular necrosis, proximal tubular nephropathy and osmotic nephrosis may occur upon use of human IGIV products. Ensure that patients are not volume depleted before administering ASCENIV. In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic medicinal products or age of >65 years), administer ASCENIV at the minimum infusion rate practicable [see Dosage and Administration (2)].

The risk of renal dysfunction and acute renal failure is greater in products that contain sucrose, though may still occur in products without sucrose. ASCENIV does not contain sucrose.

Conduct periodic monitoring of renal function and urine output is particularly important in patients at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of ASCENIV and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing ASCENIV [see Dosage and Administration (2)].

5.4 Hyperproteinemia, Hyperviscosity, and Hyponatremia

Hyperproteinemia, hyperviscosity, and hyponatremia may occur in patients receiving IGIV treatment, including ASCENIV. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap, because treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thrombotic events.

5.5 Aseptic Meningitis Syndrome

Aseptic meningitis syndrome (AMS) may occur with IGIV treatments, including ASCENIV. The risk of AMS may be higher with high doses (≥2g/kg) and/or rapid infusion of IGIV. AMS usually begins within several hours to 2 days following IGIV treatment and is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting. Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

5.6 Hemolysis

Hemolysis may occur after administration of IGIV products, including ASCENIV due to the presence of blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test and hemolysis. Delayed hemolytic anemia can develop after IGIV treatment due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, has been reported.

The risk factors for hemolysis include high doses (e.g., ≥ 2 g/kg) given either as a single administration or divided over several days, non-O blood group, and an underlying inflammatory disease condition.

Monitor patients for clinical signs and symptoms of hemolysis. If these are present after ASCENIV infusion, perform appropriate confirmatory laboratory testing. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving IGIV, perform adequate cross-matching to avoid exacerbating ongoing hemolysis.

5.7 Transfusion-Related Acute Lung Injury

Transfusion-Related Acute Lung Injury (TRALI) may occur in patients following IGIV treatment, including ASCENIV. TRALI is characterized by severe respiratory distress,

pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms typically appear within 1 to 6 hours following treatment.

Monitor patients for pulmonary adverse reactions. If TRALI is suspected, immediatly stop ASCENIV infusion, and perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient's serum.

Manage patients using oxygen therapy with adequate ventilatory support as appropriate.

5.8 Transmissible Infectious Agents

There is risk of transmitting infectious agents including viruses, the variant Creutzfeldt-Jakob disease (vCJD) and the Creutzfeldt-Jakob disease (CJD) agent with ASCENIV administration because it is manufactured using human blood. The risk of infectious agent transmission is minimized by plasma donor screening, donation testing, and manufacturing steps proven to inactivate and remove bloodborne pathogens.

All infections suspected to have been transmitted by ASCENIV should be reported by the physician or other healthcare provider to ADMA Biologics at **(1-800-458-4244)**.

5.9 Monitoring Laboratory Tests

- Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of ASCENIV and at appropriate intervals thereafter.
- Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia, markedly high triacylglycerols (triglycerides), or monoclonal gammopathies because of the potentially increased risk of thrombosis.
- If signs and/or symptoms of hemolysis are present after an infusion of ASCENIV, perform appropriate laboratory testing for confirmation.
- If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-HLA antibodies in both the product and patient's serum.

5.10 Interference with Laboratory Tests

After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs') test.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials cannot be directly compared to rates in the clinical trials of another product and may not reflect the rates observed in clinical practice.

The safety data described in this section reflects exposure to ASCENIV in two clinical studies (Study 1 and Study 2) as described below.

Study 1

In Study 1, 59 patients with PI received a total of 793 infusions of ASCENIV at a median dose of 505 mg/kg (range 284 to 1008 mg/kg) every 3 weeks or 4 weeks for up to 12 months (mean 346 days; range 36 to 385 days). Of the 793 infusions administered during this trial, 7 (11.9%) patients received premedication prior to 7 (0.9%) infusions [see Clinical Studies (14)].

The most common adverse reactions occurring in ≥5% of patients in Study 1 are presented in Table 2.

Table 2: Adverse Reactions in ≥ 5% of Patients in Study 1

Adverse Reactions*	Number (%) of Patients (N=59)	Number (%) of Infusions (N=793)
Headache	14 (24)	21 (2.6)
Sinusitis	6 (10)	7 (0.9)
Nausea	5 (9)	5 (0.6)

Acute sinusitis	4 (7)	4 (0.5)
Fatigue	4 (7)	9 (1.1)
Muscle spasms	4 (7)	4 (0.5)
Bronchitis	3 (5)	3 (0.4)
Diarrhea	3 (5)	3 (0.4)
Epistaxis	3 (5)	4 (0.5)
Muscle Pain	3 (5)	5 (0.6)
Oropharyngeal pain	3 (5)	3 (0.4)
Pain in extremity	3 (5)	3 (0.4)
Itching	3 (5)	3 (0.4)

*Adverse reactions were defined as events occurring within 72 hours after the end of an ASCENIV infusion

Study 2 (Pediatric Study)

In Study 2, 16 pediatric patients with PI aged 2 to 11 years received 91 infusions of ASCENIV at a median dose of 541 mg/kg (range 300-800 mg/kg) every 3 or 4 weeks for approximately 5 months.

The most common adverse reactions in Study 2 are presented in Table 3 below.

Table 3: Adverse Reactions in Study 2

Adverse Reactions*	**Number (%) of Patients (N=16)**	**Number (%) of Infusions (N=91)**
Chest Pain	1 (6)	1 (1)
Epistaxis	1 (6)	1 (1)
Fatigue	1 (6)	1 (1)
Hypersensitivity	1 (6)	1 (1)
Diarrhea	1 (6)	1 (1)
Headache**	4 (25)	5 (5)
Otitis**	2 (13)	2 (2)
Viral Rash	1 (6)	1 (1)
Vomiting	1 (6)	1 (1)
Nausea	3 (19)	4 (4)

*Adverse reactions were defined as events occurring within 72 hours after the end of an ASCENIV infusion

**Includes multiple related terms.

6.2 Postmarketing Experience

Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions have been identified and reported during the post-approval use of IGIV products:

- Respiratory, thoracic and mediastinal disorders: Apnea, Acute Respiratory Distress Syndrome (ARDS), cyanosis, dyspnea, bronchospasm.
- Cardiac disorders: Cardiac arrest, vascular collapse, hypotension.
- Nervous system disorder: Coma, loss of consciousness, seizures, tremor.
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, epidermolysis, erythema multiforme, bullous dermatitis.
- Blood and lymphatic system disorders: Pancytopenia, leukopenia.
- General disorders and administration site conditions: Pyrexia, rigors.
- Gastrointestinal disorders: Hepatic dysfunction, abdominal pain.

7 DRUG INTERACTIONS

Immunoglobulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, and varicella because the continued presence of high levels of passively acquired antibody may interfere with an active antibody response. Inform the immunizing physician of recent therapy with ASCENIV so that appropriate measures may be taken.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

No human data are available to indicate the presence or absence of drug-associated risk. Animal reproduction studies have not been conducted with ASCENIV. It is not known whether ASCENIV can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

Immune globulins cross the placenta from maternal circulation.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20% respectively. ASCENIV should be given to pregnant women only if clearly needed.

8.2 Lactation

Risk Summary

No human data are available to indicate the presence or absence of drug-associated risk. The developmental and health benefits of breast feeding should be considered along with the mother’s clinical need for ASCENIV and any potential adverse effects on the breast-fed infant from ASCENIV or from the underlying maternal condition.

8.4 Pediatric Use

The safety and effectiveness of ASCENIV have been established in pediatric patients with PI aged 2 years and older. The use of ASCENIV in pediatric patients was supported by evidence from two clinical studies (Study 1 and Study 2) which enrolled a total of 27 pediatric patients 2 to 16 years of age (9 children ages 2-6, 13 children ages 7-11, and 5 adolescents ages 12 – 16) with primary humoral immunodeficiency (PI) [see Adverse Reactions (6) and Clinical Studies (14)].

Safety and effectiveness has not been studied in pediatric patients with PI who are under the age of 2 years.

8.5 Geriatric Use

There were 11 patients (19%) 65 years of age and older in Study 1. Clinical studies of ASCENIV did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

10 OVERDOSAGE

With intravenous administration, overdose may lead to fluid overload and hyperviscosity. Patients at risk of complications of fluid overload and hyperviscosity include elderly patients and those with cardiac or renal impairment.

11 DESCRIPTION

ASCENIV (immune globulin intravenous, human - slra) is a purified, sterile, ready-to-use preparation of concentrated human immunoglobulin G (IgG) antibodies. The distribution of IgG subclasses is similar to that of normal plasma. The active ingredient is human immunoglobulin purified from source human plasma and processed using a modified classical Cohn Method 6 / Oncley Method 9 fractionation process as well as anion and cation exchange steps for added purification. ASCENIV contains 100 ± 10 mg/mL protein, of which not less than 96% is human immunoglobulin obtained from source human plasma. It is formulated in water for injection containing 0.100-0.140 M sodium chloride, 0.20-0.29 M glycine, 0.15–0.25% polysorbate 80, and pH 4.0–4.6.

ASCENIV contains ≤ 200 µg/mL of IgA.

Each plasma donation used for the manufacture of ASCENIV is collected from FDA-licensed facilities and undergoes rigorous testing. Plasma donations must test negative for hepatitis B virus (HBV) surface antigen (HBsAg), antibodies to human

immunodeficiency virus (HIV) strains 1 and 2 (anti-HIV-1/2), and antibodies to the hepatitis C virus (anti-HCV) as determined by enzyme immune assay (EIA). In addition, each plasma unit must test negative and/or non-reactive for HIV RNA, HCV RNA, HBV DNA, Hepatitis A Virus (HAV) RNA, and Parvovirus B19 (B19 virus) DNA as determined by Nucleic Acid Amplification Testing (NAT) of plasma minipools. NAT is also performed on a sample of the manufacturing pool and must be negative and/or non-reactive for HIV RNA, HCV RNA, HBV DNA, and Hepatatis A Virus (HAV) RNA, and the limit for B19 virus DNA in a manufacturing pool is set not to exceed 10^4 IU/mL.

The manufacturing process of ASCENIV employs six steps to remove/inactivate adventitious viruses to minimize the risk of virus transmission. The steps are "Precipitation and removal of fraction III" during cold ethanol fractionation, "Q-membrane filtration", "Solvent/detergent treatment" (TnBP / Triton X-100), "Anion exchange chromatography" and "virus filtration". In compliance with current guidelines, the steps have been separately validated in a series of in vitro experiments for their capacity to inactivate or remove both enveloped and non-enveloped viruses.

Precipitation and removal of fraction III and Q-membrane filtration removes non-enveloped viruses, solvent/detergent treatment represents a virus inactivation step for enveloped viruses, Anion exchange chromatography binds enveloped and non-enveloped viruses, and virus filtration removes both enveloped and non-enveloped viruses by size exclusion. In addition to the steps above, low pH during several steps of the production process contributes to virus inactivation. The results of virus validation studies for the ASCENIV process are shown in Table 4, expressed as $\log_{10}$ reduction factors.

Table 4: Virus Removal/Inactivation ($\log_{10}$)

Step/Virus	**HIV**	**BVDV**	**SinV**	**WNV**	**PRV**	**MEV**	**EMC**	**BPV**	**PPV**	**SV40**
Virus Type	Enveloped	Enveloped	Enveloped	Enveloped	Enveloped	Non-enveloped	Non-enveloped	Non-enveloped	Non-enveloped	Non-enveloped
Virus Family	Retro	Flavi	Flavi	Flavi	Herpes	Picorna	Picorna	Parvo	Parvo	Polyoma
Precipitation and Removal of Fraction III and Depth Filtration	-	-	-	-	-	5.29	≥5.70	-	≥5.78	2.00 *
Q-Membrane Filtration [1]	-	-	-	-	-	-	-	-	2.02	-
Solvent Detergent TNBP/Triton X-100 Treatment	≥3.92	≥5.32	>7.11	>4.96	≥4.88	-	-	-	-	-
Anion Exchange Chromatography	1.04	-	-	-	-	-	-	-	1.09	-
Virus Nanofiltration	≥4.72	≥4.67	-	-	≥4.15	-	≥6.24	6.18	4.66	>5.02
Low pH Treatment [2]	2.43	-	-	-	3.20 [2]	-	-	-	-	-
Total Clearance	≥9.68	≥9.99	> 7.11	> 4.96	≥12.23	5.29	≥5.70 [3]	6.18	11.49	> 7.02

* without depth filtration

HIV, human immunodeficiency virus; **BVDV**, Bovine viral diarrhea virus, model virus for HCV; **SinV**, Sindbis virus, model virus for HCV; **WNV**, West Nile virus; **PRV**, Pseudorabies virus, model virus for herpes viruses and Hepatitis B virus; **MEV**, Murine encephalomyelitis virus, model virus for hepatitis A virus; **BPV**, Bovine parvovirus, model virus for human B19 virus; **PPV**, Porcine parvovirus, model virus for human B19 virus; **SV40**, Simian virus 40, model virus for highly resistant non-enveloped viruses. **EMC**, Encephalomyocarditis virus, model virus for hepatitis A virus

1 Q-membrane filtration step is associated with the affinity stream part of the production process.

2 Low pH treatment included in total clearance calculation based on separate mode of inactivation than VRF.

3 EMC total clearance was calculated with the most conservative approach of using the lowest reduction value (≥5.70) between the Fraction III precipitation/ filtration and nanofiltration steps.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

ASCENIV is a replacement therapy for patients with primary humoral immunodeficiency (PI). ASCENIV provides a broad spectrum of opsonizing and neutralizing IgG antibodies

against bacterial and viral pathogens and their toxins. The mechanism of action has not been fully elucidated in PI.

12.2 Pharmacodynamics

ASCENIV contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against various infectious agents, reflecting the IgG activity found in the donor population. ASCENIV which is prepared from pooled plasma from not less than 1,000 donors, has an IgG subclass distribution similar to that of native human plasma. Adequate doses of IGIV can restore an abnormally low IgG level to the normal range. Standard pharmacodynamics studies were not performed.

12.3 Pharmacokinetics

Two open-label studies were carried out in patients with Primary Immunodeficiency (PI) to assess the pharmacokinetics, safety, and tolerability of IgG after intravenous (IV) administration of ASCENIV. In Study 1, adults, adolescents, and children patients with PI were evaluated. A total of 26 adult and 4 pediatric patients received ASCENIV every 21 days at doses from 291 mg/kg to 654 mg/kg or every 28 days at doses from 299 mg/kg to 760 mg/kg and were eligible for pharmacokinetic analysis. In Study 2, 16 pediatric patients received ASCENIV every 21 days at doses from 388 mg/kg to 651 mg/kg or every 28 days at doses from 183 mg/kg to 929 mg/kg and completed either sparse (ages 2-6) or full (ages 7-11) PK sampling based on their age. No specific dose requirements were necessary to achieve the targeted serum IgG levels in the pediatric patients. The pharmacokinetic parameters for IgG from both studies of ASCENIV are summarized by age group in Table 5.

Table 5: Total IgG Pharmacokinetic Parameters of ASCENIV by Age

a) PK Parameters: 3 Week Schedule – Mean (SD)**

Parameter	6-<12 Years	12-16 Years	> 16 years
N*	3	1	8
Cmax (mg/dL)	1,767 (342)	2,416	2,522 (416)
Cmin (mg/dL)	1,098 (425)	1,542	1,147 (287)
AUC(0-tau) (hr×mg/dL)	564,862 (160,789)	881,606	786,380 (163,481)
CL (mL/hr/kg)	0.09 (0.004)	0.05	0.07 (0.02)
Vz (mL/kg)	99.8 n=1	—†	76.8 (13.5) n=6
t½ (days)	32.6 n=1	—†	28.5 (4.4) n=6

b) PK Parameters: 4 Week Schedule – Mean (SD)

Parameter	2-<6 Years	6-<12 Years	12-16 Years	> 16 years
N*	4	4	1	18
Cmax (mg/dL)	1,593 (160)	2,473 (792)	3,592	2,195 (483)
Cmin (mg/dL)	946 (115)	1,558 (480)	1,192	928 (244)
AUC(0-tau) (hr×mg/dL)	—†	974,136 (135,653) n=3	1,112,453	850,233 (228,781)
CL (mL/hr/kg)	—†	0.07 (0.02) n=3	0.06	0.06 (0.02)
Vz (mL/kg)	—†	138 (22.4) n=2	—†	86.9 (25.4) n=12
		60.5		37.1

t½ (days)	—†	(14.3) n=2	—†	(7.2) n=12

*Divergent number of patients for individual PK parameters are indicated in the applicable cells.

†Parameter could not be calculated for any subject.

N = number of patients; AUC(0-tau) = area under the serum concentration-time curve to the last concentration ≥ LLOQ; CL = total body clearance; Cmax = maximum concentration; Cmin = minimum concentration; t½ = terminal half-life; Vz = volume of distribution

**Neither study contained evaluable patients aged 2-<6 years on a 3-week dosing regimen.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No animal studies were conducted to evaluate the carcinogenic or mutagenic effects of ASCENIV or its effects on fertility.

13.2 Animal Toxicology and/or Pharmacology

No animal studies were conducted to evaluate possible toxicity of ASCENIV.

ASCENIV contains Polysorbate 80; Intravenous administrations of Polysorbate 80 in multiple species have been linked with a decrease in blood pressure. In rats, single doses of Polysorbate 80 that were up to 25 times higher than the amount from 800 mg/kg ASCENIV resulted in an increase of liver enzymes and total bilirubin.

14 CLINICAL STUDIES

Study 1

A prospective, open-label, single-arm, multicenter trial assessed the efficacy, safety, and pharmacokinetics of ASCENIV in adult and pediatric patients with PI. Study patients were receiving regular IGIV replacement therapy, with a stable dose between 300 and 800 mg/kg for at least 3 months prior to participation in this trial. Patients received an ASCENIV infusion administered every 3 or 4 weeks (both the dose and schedule depending on their prior therapy) for 12 months.

A total of 59 patients were enrolled into the study. The population characteristics were as follows: The mean age was 42 years (range 3 to 74 years) including 11 pediatric patients, 31 patients (53%) were female, 58 patients (98%) were Caucasian, 3 patients (5%) were Hispanic and 1 patient (2%) was African American.

There were 19 patients with a 3-week cycle and 40 patients with a 4-week cycle. There were 45 patients (76%) with common variable immunodeficiency (CVID) as their primary diagnosis, followed by X-linked Agammaglobulinemia (10%), Antibody Deficiencies and 'Other' (7% each). The modified intent-to-treat (mITT) population included 59 patients and was used for efficacy analysis.

The primary efficacy measure was the rate of serious bacterial infections (SBIs), defined bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscess, and bacterial meningitis per person-year. The predefined success criteria was demonstration of rate of less than one acute SBI per patient per year. Secondary efficacy parameters included time to first SBI and time to first infection of any kind/seriousness, days on antibiotics (excluding prophylaxis), days off school/work due to infections, all confirmed infections of any kind or seriousness, and hospitalizations due to infection.

Table 6: Summary of Efficacy Results in Study 1

Number of Patients (mITT Population)	59
Total Number of person-years [a]	55.9
Infections	
Number of confirmed serious acute bacterial infections [b]	0

Rate of SBIs (SBIs/total person-years)	0.0
Rate of Infections (Infections/total person-years) [a]	3.4
Antibiotic use due to infection [c]	
Number of patients (%)	37 (63%)
Days per patient per year	32.9
Days off school/daycare/work due to infection	
Number of persons with days off of school, daycare or work due to infections	23 (39%)
Total days	93
Days per patient per year	1.7
Unscheduled Medical Visits due to infection	
Number of persons with unscheduled medical visits due to infections (%)	24 (41%)
Total visits	54
Visits per patient per year	0.97
Hospitalization due to infection	
Number of patients(%)	1 (1.7%)
Number of Days	5
Hospitalizations per patient per year	0.02

SBI = serious bacterial infections.

[a]Person-years: Person-time in years with 2 decimals = (the Final Clinical Visit Date - the Day 0 date+1) / 365.25, where the final clinical visit date is defined as the specimen collection date of the final clinical visit for urinalysis, or the specimen collection date for the clinical laboratory tests at the final clinical visit and Day 0 date is the start date of the first ASCENIV infusion.

[b] Defined as bacterial pneumonia, bacterial meningitis, bacteremia/septicemia, osteomyelitis/septic arthritis, and visceral abscess.

[c] The calculation of antibiotic use includes patients who received antibiotics for therapeutic use.

Study 2 (Pediatric Study)

A prospective, open-label, single-arm, multi-center study evaluating the pharmacokinetics, efficacy, and safety of ASCENIV was conducted in 16 pediatric patients with PI. All patients had confirmed and documented clinical diagnosis of PI, including hypogammaglobulinemia or agammaglobulinemia.

Patients received an ASCENIV infusion administered every 3 or 4 weeks (based on the dose and schedule of their prior treatment regimen) for approximately 5 months. The population characteristics was as follows: The median age was 8 years (2 to 11 years), 11 patients (69%) were male, 12 patients (75%) were White, 3 patients (19%) were African American, and 1 patient (6%) was of “other” race.

The primary efficacy measure was the rate of acute serious bacterial infections (SBIs) defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, or visceral abscess. The predefined success criteria was demonstration of rate of less than one acute SBI per patient per year.

No acute SBIs occurred during the six -month observation period, yielding a mean number of acute SBI episodes per person-year of 0.0. No other serious infections, or hospitalizations due to infections occurred.

16 HOW SUPPLIED/STORAGE AND HANDLING

ASCENIV is supplied in a single-use, tamper-evident vial. The components used in the packaging for ASCENIV are not made with natural rubber latex. ASCENIV is supplied in 50 mL size containing 5 grams of protein (NDC 69800-0250-1).

- Store at 2 to 8°C (36 to 46°F) for up to 36 months from the date of manufacture. Do not freeze.
- Product may be stored up to 4 weeks at ≤ 25° C (77° F). After storage at room temperature product must be used or discarded.

17 PATIENT COUNSELING INFORMATION

Instruct patients taking ASCENIV to immediately report symptoms of:

- *Thrombosis* which includes pain and/or swelling of an arm or legs/feet with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, acute chest pain or discomfort that worsens on deep breathing, unexplained rapid pulse, numbness or weakness on one side of the body (see Warning and Precaution [5.2]).
- *Renal Injury* which includes decreased urine output, sudden weight gain, fluid retention/edema, and/or shortness of breath. Such symptoms may suggest kidney damage (see Boxed Warning, Warnings and Precautions [5.3]).
- *Aseptic Meningitis Syndrome (AMS)* which includes severe headache, neck stiffness, drowsiness, fever, sensitivity to light, painful eye movements, nausea and vomiting (see Warnings and Precautions [5.5]).
- *Hemolysis* which includes fatigue, increased heart rate, yellowing of skin or eyes, dark- colored urine (see Warnings and Precautions [5.6]).
- *Transfusion-Related Acute Lung Injury (TRALI)* which includes trouble breathing, chest pain, blue lips or extremities, fever (see Warnings and Precautions [5.7])

Inform patients that ASCENIV:

- Is made from human plasma and may contain infectious agents that can cause disease. While the risk that ASCENIV can transmit an infection has been reduced by screening plasma donors for prior exposure, testing donated plasma, and inactivating or removing certain viruses during manufacturing, patients should report any symptoms that concern them (see Description [11] and Warnings and Precautions [5.8]).
- Can interfere with their immune response to live viral vaccines (e.g., measles, mumps, rubella, and varicella). Instruct patients to notify their healthcare professional of this potential interaction when they are receiving vaccinations (see Drug Interactions [7]).

Manufactured by ADMA Biologics

Boca Raton, FL 33487 USA

U.S. License No. 2019

RM-5640 Rev.005

NDC: 69800-0250-2 - Vial Label



NDC: 69800-0250-1 - Carton Label



ASCENIV

human immunoglobulin g liquid

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:69800-0250
Route of Administration	INTRAVENOUS		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**

HUMAN IMMUNOGLOBULIN G (UNII: 66Y330CJHS) (HUMAN IMMUNOGLOBULIN G - UNII:66Y330CJHS)	HUMAN IMMUNOGLOBULIN G	5 g in 50 mL

Inactive Ingredients

Ingredient Name	Strength
GLYCINE (UNII: TE7660XO1C)	
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	
WATER O-18 (UNII: 7QV8F8BYNJ)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:69800-0250-1	1 in 1 CARTON	04/01/2019	
1	NDC:69800-0250-2	50 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA125590	04/01/2019	

Labeler - ADMA Biologics, Inc. (117213235)

Establishment

Name	Address	ID/FEI	Business Operations
ADMA Biologics, Inc		117213235	manufacture(69800-0250)

Revised: 9/2026 ADMA Biologics, Inc.